A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma-Reference-Cited by-同舟云学术

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

Published:2005 Issue:10 Volume:103 Page:2035-2041
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rosenberg Jonathan E.,von der Maase Hans,Seigne John D.,Mardiak Jozef,Vaughn David J.,Moore Malcolm,Sahasrabudhe Deepak,Palmer Peter A.,Perez-Ruixo Juan Jose,Small Eric J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

2. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

3. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

4. Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy

5. DOCETAXEL AND IFOSFAMIDE AS SECOND LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE OF PLATINUM CHEMOTHERAPY: A PHASE 2 STUDY

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of targeted therapies for advanced urothelial carcinoma;Exploration of Targeted Anti-tumor Therapy;2024-06-21

2. Targeting HRAS in Head and Neck Cancer;The Cancer Journal;2022-09

3. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations;Clinical Cancer Research;2020-07-07

4. Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison;Journal of Comparative Effectiveness Research;2020-02

5. Biology, pathology, and therapeutic targeting of RAS;Advances in Cancer Research;2020